Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214500 · ClinicalTrials.gov registry record · Phase 2
A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
A Phase 2 study, sponsored by Amicus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00214500 is a Phase 2 study that has completed, run by Amicus Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT00214500, a Phase 2 study, has completed, sponsored by Amicus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
Interventions
- DRUG migalastat HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-01-02 |
| Est. Completion | 2008-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214500
The ClinicalTrials.gov registry entry for NCT00214500 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which migalastat HCl is the first listed.
NCT00214500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00214500 about?
NCT00214500 is a clinical study titled "A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease". Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
What is the current status of trial NCT00214500?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2006-01-02. Estimated completion is 2008-01-29.
What interventions are being tested in trial NCT00214500?
The interventions under investigation include: migalastat HCl (DRUG).
Who is sponsoring clinical trial NCT00214500?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.